Latest Earnings Results: Q2 '26
Estimated EPS
-$0.80
Reported EPS
-$0.80
Surprise
-0.09%
Estimated Rev
$12.98M
Reported Rev
$7.66M
Surprise
-40.99%
• Reported GAAP EPS of -$0.80 up 18.37% YoY • Reported revenue of $7.66M down -46.23% YoY • Intellia Therapeutics expects FDA acceptance of its biologics license application for lonvo-z in the second half of 2026 and plans to launch lonvo-z commercially in the first half of 2027.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | -$0.80 | -- | -- | N/A |
Q2 '26 | -$0.80 | -$0.80 | -0.09% | MISSED |
Q1 '26 | -$0.91 | -$0.81 | 11.06% | BEAT |
Q4 '25 | -$0.94 | -$0.83 | 11.81% | BEAT |
Q3 '25 | -$1.01 | -$0.92 | 8.50% | BEAT |